A study has made a new discovery in cancer signaling and has revealed that it could have important implications for the development of new classes of cancer therapeutics.

Indoor tanning beds do far more than darken the skin. A new study shows they nearly triple the risk of melanoma by causing widespread DNA damage across almost the entire skin surface — including areas rarely exposed to sunlight — offering the clearest molecular evidence yet of how tanning beds drive the deadliest form of skin cancer.

Why does a high-fat diet raise liver cancer risk decades later? A new MIT study traces the answer to a slow cellular identity shift that turns survival into vulnerability.

From tuberculosis to lung cancer, a new personalised lung-on-chip model opens the door to studying respiratory diseases in a realistic human system for the first time.

A new study has recommended to expand the universal age-based screening from the current 50-80 years to 40-85 years. The researchers estimate that this would help to detect 94 % of lung cancers and thus, prevent more than 26,000 extra deaths annually.

In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of a common chemotherapy drug, making it dramatically more soluble and effective and less toxic.

The Orion project is part of the flagship initiative, ‘Artificial Intelligence in the Life Sciences, from a Human Health Perspective’ by Swiss Federal Innovation Agency Innosuisse. The goal of the research project is to help improve the treatment of each cancer patient.

A new method can produce custom-designed proteins in just 4-6 weeks that can arm the T cells of the body's immune system to attack and kill cancer cells.

A new study has revealed that even a few mutated cells can significantly impact the entire blood-forming system. This new finding could potentially change the way doctors treat their cancer patients.

Genetic testing for key gene variants before chemotherapy can cut severe side effects nearly in half for gastrointestinal cancer patients, a Penn Medicine study shows — paving the way for safer, more personalized treatment.